Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Apr;79(11-12):1742–1745. doi: 10.1038/sj.bjc.6690277

Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma

R Hoffmann 1, A Franzke 1, J Buer 2, S Sel 1, K Oevermann 1, A Duensing 1, M Probst 1, S Duensing 1, H Kirchner 1, A Ganser 1, J Atzpodien 1
PMCID: PMC2362808  PMID: 10206286

Abstract

The purpose of the study was to determine prognostic significance of pretreatment serum levels of different molecules involved in cell to cell interactions along with other clinical parameters in patients with metastatic renal cell carcinoma. sICAM-1, sVCAM-1 and sELAM-1 serum levels were determined by ELISA assays in sera from 99 patients with histologically confirmed progressive metastatic renal cell carcinoma prior to initiation of systemic therapy. Kaplan–Meier survival analysis, log-rank statistics and two-proportional Cox regression analyses were employed to identify risk factors and to demonstrate statistical independence. In univariate analyses, the following pretreatment risk factors could be identified: serum sICAM-1 level > 360 ng ml−1, erythrocyte sedimentation rate > 70 mm h−1, serum C-reactive protein level > 8 mg l−1, serum lactic dehydrogenase level > 240 U/ l and neutrophil count > 6000 μl−;1. Multivariate analyses demonstrated statistical independence for serum sICAM-1 level, erythrocyte sedimentation rate (ESR) and serum C-reactive protein (CRP) level as pretreatment predictors of overall patient survival. The prognostic significance of sICAM-1 might indicate a role of this molecule for tumour progression, potentially in association with the abrogation of anti-tumour immune responses. The possibility of defining a pretreatment risk model based on sICAM-1 level, ESR and CRP also warrants further investigation, with regard to a possible linkage between acute phase proteins and sICAM-1 levels. © 1999 Cancer Research Campaign

Keywords: renal carcinoma, soluble adhesion molecules, predictor

Full Text

The Full Text of this article is available as a PDF (80.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amblard F., Auffray C., Sekaly R., Fischer A. Molecular analysis of antigen-independent adhesion forces between T and B lymphocytes. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3628–3632. doi: 10.1073/pnas.91.9.3628. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anastassiou G., Duensing S., Steinhoff G., Kirchner H., Ganser A., Atzpodien J. In vivo distribution of integrins in renal cell carcinoma: integrin-phenotype alteration in different degrees of tumor differentiation and VLA-2 involvement in tumor metastasis. Cancer Biother. 1995 Winter;10(4):287–292. doi: 10.1089/cbr.1995.10.287. [DOI] [PubMed] [Google Scholar]
  3. Atzpodien J., Körfer A., Franks C. R., Poliwoda H., Kirchner H. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet. 1990 Jun 23;335(8704):1509–1512. doi: 10.1016/0140-6736(90)93039-r. [DOI] [PubMed] [Google Scholar]
  4. Becker J. C., Termeer C., Schmidt R. E., Bröcker E. B. Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol. 1993 Dec 15;151(12):7224–7232. [PubMed] [Google Scholar]
  5. Boyd A. W., Wawryk S. O., Burns G. F., Fecondo J. V. Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell-cell contact-mediated immune mechanisms. Proc Natl Acad Sci U S A. 1988 May;85(9):3095–3099. doi: 10.1073/pnas.85.9.3095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chong A. S., Boussy I. A., Jiang X. L., Lamas M., Graf L. H., Jr CD54/ICAM-1 is a costimulator of NK cell-mediated cytotoxicity. Cell Immunol. 1994 Aug;157(1):92–105. doi: 10.1006/cimm.1994.1208. [DOI] [PubMed] [Google Scholar]
  7. Christiansen I., Enblad G., Kälkner K. M., Gidlöf C., Glimelius B., Tötterman T. H. Soluble ICAM-1 in Hodgkin's disease: a promising independent predictive marker for survival. Leuk Lymphoma. 1995 Oct;19(3-4):243–251. doi: 10.3109/10428199509107894. [DOI] [PubMed] [Google Scholar]
  8. Christiansen I., Gidlof C., Kälkner K M., Hagberg H., Bennmarker H., Tötterman T. Elevated serum levels of soluble ICAM-1 in non-Hodgkin's lymphomas correlate with tumour burden, disease activity and other prognostic markers. Br J Haematol. 1996 Mar;92(3):639–646. doi: 10.1046/j.1365-2141.1996.00377.x. [DOI] [PubMed] [Google Scholar]
  9. Fecondo J. V., Kent S. B., Boyd A. W. Inhibition of intercellular adhesion molecule 1-dependent biological activities by a synthetic peptide analog. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2879–2882. doi: 10.1073/pnas.88.7.2879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Foreman N. K., Rill D. R., Coustan-Smith E., Douglass E. C., Brenner M. K. Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication. Br J Cancer. 1993 May;67(5):933–938. doi: 10.1038/bjc.1993.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Franzke A., Probst-Kepper M., Buer J., Duensing S., Hoffmann R., Wittke F., Volkenandt M., Ganser A., Atzpodien J. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer. 1998 Jul;78(1):40–45. doi: 10.1038/bjc.1998.439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hatzistilianou M., Athanassiadou F., Agguridaki C., Catriu D. Circulating soluble adhesion molecule levels in children with acute lymphoblastic leukaemia. Eur J Pediatr. 1997 Jul;156(7):537–540. doi: 10.1007/s004310050657. [DOI] [PubMed] [Google Scholar]
  13. Heicappell R., Podlinski J., Buszello H., Ackermann R. Cell surface expression and serum levels of intercellular adhesion molecule-1 in renal cell carcinoma. Urol Res. 1994;22(1):9–15. doi: 10.1007/BF00431542. [DOI] [PubMed] [Google Scholar]
  14. Ljungberg B., Grankvist K., Rasmuson T. Serum acute phase reactants and prognosis in renal cell carcinoma. Cancer. 1995 Oct 15;76(8):1435–1439. doi: 10.1002/1097-0142(19951015)76:8<1435::aid-cncr2820760821>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  15. Maio M., Pinto A., Carbone A., Zagonel V., Gloghini A., Marotta G., Cirillo D., Colombatti A., Ferrara F., Del Vecchio L. Differential expression of CD54/intercellular adhesion molecule-1 in myeloid leukemias and in lymphoproliferative disorders. Blood. 1990 Aug 15;76(4):783–790. [PubMed] [Google Scholar]
  16. Makgoba M. W., Sanders M. E., Ginther Luce G. E., Gugel E. A., Dustin M. L., Springer T. A., Shaw S. Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity. Eur J Immunol. 1988 Apr;18(4):637–640. doi: 10.1002/eji.1830180423. [DOI] [PubMed] [Google Scholar]
  17. Marlin S. D., Springer T. A. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell. 1987 Dec 4;51(5):813–819. doi: 10.1016/0092-8674(87)90104-8. [DOI] [PubMed] [Google Scholar]
  18. Meyer D. M., Dustin M. L., Carron C. P. Characterization of intercellular adhesion molecule-1 ectodomain (sICAM-1) as an inhibitor of lymphocyte function-associated molecule-1 interaction with ICAM-1. J Immunol. 1995 Oct 1;155(7):3578–3584. [PubMed] [Google Scholar]
  19. Moy V. T., Brian A. A. Signaling by lymphocyte function-associated antigen 1 (LFA-1) in B cells: enhanced antigen presentation after stimulation through LFA-1. J Exp Med. 1992 Jan 1;175(1):1–7. doi: 10.1084/jem.175.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Natali P. G., Hamby C. V., Felding-Habermann B., Liang B., Nicotra M. R., Di Filippo F., Giannarelli D., Temponi M., Ferrone S. Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res. 1997 Apr 15;57(8):1554–1560. [PubMed] [Google Scholar]
  21. Natali P., Nicotra M. R., Cavaliere R., Bigotti A., Romano G., Temponi M., Ferrone S. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res. 1990 Feb 15;50(4):1271–1278. [PubMed] [Google Scholar]
  22. Passlick B., Izbicki J. R., Simmel S., Kubuschok B., Karg O., Habekost M., Thetter O., Schweiberer L., Pantel K. Expression of major histocompatibility class I and class II antigens and intercellular adhesion molecule-1 on operable non-small cell lung carcinomas: frequency and prognostic significance. Eur J Cancer. 1994;30A(3):376–381. doi: 10.1016/0959-8049(94)90259-3. [DOI] [PubMed] [Google Scholar]
  23. Reinhardt K. M., Steiner M., Zillig D., Nagel H. R., Blann A. D., Brinckmann W. Soluble intercellular adhesion molecule-1 in colorectal cancer and its relationship to acute phase proteins. Neoplasma. 1996;43(2):65–67. [PubMed] [Google Scholar]
  24. Rothlein R., Mainolfi E. A., Czajkowski M., Marlin S. D. A form of circulating ICAM-1 in human serum. J Immunol. 1991 Dec 1;147(11):3788–3793. [PubMed] [Google Scholar]
  25. Schadendorf D., Diehl S., Zuberbier T., Schadendorf C., Henz B. M. Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. Dermatology. 1996;192(2):89–93. doi: 10.1159/000246328. [DOI] [PubMed] [Google Scholar]
  26. Shimizu Y., Minemura M., Tsukishiro T., Kashii Y., Miyamoto M., Nishimori H., Higuchi K., Watanabe A. Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis. Hepatology. 1995 Aug;22(2):525–531. [PubMed] [Google Scholar]
  27. Sung K. L., Kuhlman P., Maldonado F., Lollo B. A., Chien S., Brian A. A. Force contribution of the LFA-1/ICAM-1 complex to T cell adhesion. J Cell Sci. 1992 Sep;103(Pt 1):259–266. doi: 10.1242/jcs.103.1.259. [DOI] [PubMed] [Google Scholar]
  28. Vora A. R., Rodgers S., Parker A. J., Start R., Rees R. C., Murray A. K. An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma. Br J Cancer. 1997;76(7):836–844. doi: 10.1038/bjc.1997.472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Welder C. A., Lee D. H., Takei F. Inhibition of cell adhesion by microspheres coated with recombinant soluble intercellular adhesion molecule-1. J Immunol. 1993 Mar 15;150(6):2203–2210. [PubMed] [Google Scholar]
  30. Wolff J. M., Stephenson R. N., Chisholm G. D., Habib F. K. Levels of circulating intercellular adhesion molecule-1 in patients with metastatic cancer of the prostate and benign prostatic hyperplasia. Eur J Cancer. 1995;31A(3):339–341. doi: 10.1016/0959-8049(94)00446-c. [DOI] [PubMed] [Google Scholar]
  31. van de Stolpe A., van der Saag P. T. Intercellular adhesion molecule-1. J Mol Med (Berl) 1996 Jan;74(1):13–33. doi: 10.1007/BF00202069. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES